Brief: Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma
02/11/2023 13:09
Nov 2 (Reuters) - Arcellx Inc ACLX.O :
* ARCELLX ANNOUNCES ORAL PRESENTATION FOR ITS CART-DDBCMA
PHASE 1
TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
AT THE 65TH ASH ANNUAL MEETING AND EXPOSITION
Source text for Eikon: ID:nPn9JKkTba
Further company coverage: ACLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcellx
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 02:18 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Gilead Extends Tender Offer To Acquire Arcellx
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite